Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neurofibromatoses × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 72 Leukemia 38 Gastrointestinal Stromal Tumors 29 Precursor Cell Lymphoblastic Leukemia-Lymphoma 26 Leukemia, Myeloid, Chronic-Phase 26 Blast Crisis 11 Brain Neoplasms 10 Neoplasms 9 Neoplasm Metastasis 9 Melanoma 9 Lung Neoplasms 9 Gliosarcoma 8 Glioblastoma 8 Prostatic Neoplasms 7 Leukemia, Myeloid, Acute 7 Leukemia, Myeloid, Accelerated Phase 6 Glioma 6 Carcinoma, Non-Small-Cell Lung 6 Philadelphia Chromosome 5 Oligodendroglioma 5 Primary Myelofibrosis 4 Head and Neck Neoplasms 4 Central Nervous System Neoplasms 4 Astrocytoma 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Small Cell Lung Carcinoma 3 Sarcoma 3 Recurrence 3 Polycythemia Vera 3 Pancreatic Neoplasms 3

Interventions

Surveys and Questionnaires 2 talimogene laherparepvec 1 pirfenidone 1 nilotinib 1 mirdametinib 1 diphenylcyclopropenone 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sirolimus 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Lidocaine 1 Lasers, Solid-State 1 Lasers 1 Imatinib Mesylate 1 Glycopyrrolate 1 Dexmedetomidine 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01140360 2017-07-02

0908-09

Indiana University

Phase 1/2 Completed

21 enrolled 8 charts

Neurofibroma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon ⚡